<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308720</url>
  </required_header>
  <id_info>
    <org_study_id>19-003532</org_study_id>
    <nct_id>NCT04308720</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer</brief_title>
  <official_title>Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the trends of circulating tumor DNA (ctDNA) and
      changes in immune cells (T cells) during and following radiation treatment for breast cancer.
      You have been asked to take part in this research because you are being treated with
      radiation therapy for breast cancer and will have radiation treatment to your lymph nodes.

      Patients will be asked to participate in 3-4 blood draws, 60 mL each, during radiation
      treatment and allow study staff to review medical records.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the ctDNA detection rate in mutational load in breast cancer patients with indications of regional nodal irradiation.</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the proportion of patients with detectable ctDNA at the end of treatment and 3 months compared to baseline.</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The correlation of detectible ctDNA at each time point with invasive recurrence-free survival</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        18 years or older, any gender.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Histological confirmation of primary or recurrent invasive breast cancer with plans
             for adjuvant radiation therapy at the Mayo Clinic.

          -  Must have had lumpectomy or mastectomy

          -  Must have indication for regional nodal irradiation

          -  Willing to sign consent and express understanding of this protocol and its
             requirements, risks, and discomforts

          -  Must have completed final breast surgery including re-excision of margins for invasive
             cancer and DCIS or Chemotherapy within 90 days prior to registration but no sooner
             that 21 days prior to RT start

          -  Oligometastatic breast cancer (â‰¤ 3 sites of metastases) is permitted provided that the
             disease is managed with curative intent

          -  Bilateral breast cancer is permitted

          -  Positive or close margins is allowed

        Exclusion Criteria:

          -  History of prior malignancy &lt; 2 years of enrollment, except non-melanotic skin cancer
             or carcinoma-in-situ of the cervix

          -  Pregnancy or lactation

          -  Inability to understand consent or stay compliant with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Mutter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Schneider</last_name>
    <phone>507-293-1230</phone>
    <email>schneider.jessica1@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Schneider</last_name>
      <phone>507-293-1230</phone>
      <email>schneider.jessica1@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Robert Mutter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

